The pharmaceutical company Almirall returned to the path of profit in 2022 after achieving a profit of 4.3 million euros, compared to the 40.9 million loss of the previous year, as reported to the markets on Monday. Investors have reacted positively to the data, with shares rising about 6% after the release.
Revenues increased 5%, to 878.5 million euros, thanks to the boost in the dermatology business thanks to new launches. In Europe, this area increased turnover by 18.4%, to 338.2 million.
The gross operating result (ebitda) totaled 198.3 million euros in 2022, with a 16% decrease that the company attributes to the greater investment in R&D and the increase in general and administrative expenses. The latter increased 4.3%, to 409.7 million.
“We are satisfied with our solid financial results, meeting our financial estimates, thanks to the excellent evolution of our main business, dermatology, which continues to register good results”, stressed the president and CEO, Carlos Gallardo.
By 2023, the goal has been set to achieve an ebitda of between 165 and 180 million euros, and an increase in core sales (excluding AstraZeneca and Covis) “from low to medium single digits”.
The board of directors has asked Gallardo to continue as CEO, temporarily suspending a new CEO “following the company’s positive evolution, performance and momentum towards its key priorities in recent months.” Last November, the then CEO, Gianfranco Nazzi, stepped aside.
In any case, a new Governance Committee will be created to check and balance the position of the president and CEO.
